Skye Bioscience holders sell 33,892 shares
5AM-affiliated funds reported net sales of Skye Bioscience Common Stock while remaining significant indirect shareholders after the recent 1-for-8 reverse stock split.
Rhea-AI Filing Summary
Skye Bioscience, Inc. (SKYE) had affiliated investment funds managed by 5AM entities report open-market sales of its Common Stock on September 16, 2026. 5AM Ventures II, L.P. sold 32,607 shares and 5AM Co-Investors II, L.P. sold 1,285 shares at a weighted average price of $1.91 per share, leaving them with 142,463 and 5,616 shares, respectively, held indirectly. Another affiliated fund, 5AM Ventures VII, L.P., reported an indirect holding of 981,269 shares. A 1-for-8 reverse stock split effective August 24, 2026 is reflected in these amounts, and no Rule 10b5-1 trading plan is reported.
Positive
- None.
Negative
- None.
Insider Trade Summary
Net Seller: 33,892 shares
Net Sell
3 txns
Insider
5AM Partners VII, LLC, 5AM Ventures VII, L.P., 5AM Partners II, LLC, 5AM Ventures II LP, 5AM CO-INVESTORS II LP, DIEKMAN JOHN D, PARMAR KUSH, ROCKLAGE SCOTT M
Role
10% Owner | 10% Owner | 10% Owner | 10% Owner | 10% Owner | 10% Owner | 10% Owner | 10% Owner
Sold
33,892 shs ($65K)
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Sale | Common Stock F1, F2 | 32,607 | $1.91 | $62K |
| Sale | Common Stock F1, F3 | 1,285 | $1.91 | $2K |
| holding | Common Stock F4 | -- | -- | -- |
Holdings After Transaction:
Common Stock — 142,463 shares (Indirect, By 5AM Ventures II, L.P.);
Common Stock — 5,616 shares (Indirect, By 5AM Co-Investors II, L.P.);
Common Stock — 981,269 shares (Indirect, By 5AM Ventures VII, L.P.)
Footnotes (4)
- F1. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.70 to $2.11 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- F2. The securities are directly held by 5AM Ventures II, L.P. ("Ventures II"). 5AM Partners II, LLC ("Partners II") is the sole general partner of Ventures II. Dr. John Diekman, Andrew J. Schwab and Dr. Scott M. Rocklage are the managing members of Partners II and may be deemed to have shared voting and investment power over the securities beneficially owned by Ventures II. Each of Partners II, Dr. Diekman and Dr. Rocklage disclaims beneficial ownership of such securities except to the extent of its or his respective pecuniary interest therein. Mr. Schwab is a director of the Issuer and files separate Section 16 reports.
- F3. The securities are directly held by 5AM Co-Investors II, L.P. ("Co-Investors II"). Partners II is the sole general partner of Co-Investors II. Dr. John Diekman, Andrew J. Schwab and Dr. Scott M. Rocklage are the managing members of Partners II and may be deemed to have shared voting and investment power over the securities beneficially owned by Co-Investors II. Each of Partners II, Dr. Diekman and Dr. Rocklage disclaims beneficial ownership of such shares except to the extent of its or his respective pecuniary interest therein. Mr. Schwab is a director of the Issuer and files separate Section 16 reports.
- F4. The securities are directly held by 5AM Ventures VII, L.P. ("Ventures VII"). 5AM Partners VII, LLC ("Partners VII") is the sole general partner of Ventures VII. Dr. Kush Parmar and Andrew J. Schwab are the managing members of Partners VII and may be deemed to have shared voting and investment power over the securities beneficially owned by Ventures VII. Each of Partners VII and Dr. Parmar disclaims beneficial ownership of such securities except to the extent of its or his respective pecuniary interest therein. Mr. Schwab is a director of the Issuer and files separate Section 16 reports.
Key Figures
Shares sold by 5AM Ventures II, L.P.: 32,607 shares
Shares sold by 5AM Co-Investors II, L.P.: 1,285 shares
Weighted average sale price: $1.91 per share
+5 more
8 metrics
Shares sold by 5AM Ventures II, L.P.
32,607 shares
Open-market or private sale of Skye Bioscience Common Stock on September 16, 2026
Shares sold by 5AM Co-Investors II, L.P.
1,285 shares
Open-market or private sale of Skye Bioscience Common Stock on September 16, 2026
Weighted average sale price
$1.91 per share
Sales on September 16, 2026; individual prices ranged from $1.70 to $2.11
Price range for reported sales
$1.70–$2.11 per share
Range of prices for multiple transactions included in the weighted average
Shares held after by 5AM Ventures II, L.P.
142,463 shares
Indirect beneficial ownership of Skye Bioscience Common Stock after September 16, 2026 sale
Shares held after by 5AM Co-Investors II, L.P.
5,616 shares
Indirect beneficial ownership of Skye Bioscience Common Stock after September 16, 2026 sale
Indirect holding by 5AM Ventures VII, L.P.
981,269 shares
Reported beneficial ownership of Skye Bioscience Common Stock
Reverse stock split ratio
1-for-8
Reverse stock split of Skye Bioscience Common Stock effective August 24, 2026
Key Terms
reverse stock split, weighted average price, beneficial ownership, indirect ownership, +1 more
5 terms
reverse stock split financial
"On August 24, 2026, the Issuer effected a 1-for-8 reverse stock split"
A reverse stock split reduces a company's number of outstanding shares while raising the price per share proportionally, so the total value of each investor's holding is unchanged; a 1-for-10 split turns 100 shares worth $1 each into 10 shares worth $10 each. Companies often do this to regain compliance with an exchange's minimum price rule or to attract investors who avoid very low-priced stocks.
weighted average price financial
"The price reported in Column 4 is a weighted average price."
Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.
beneficial ownership financial
"may be deemed to have shared voting and investment power over the securities beneficially owned"
Beneficial ownership means the person or entity that actually enjoys the benefits of owning shares or other assets — such as receiving dividends, voting rights, or price gains — even if the legal title is held in another name. For investors it matters because knowing who truly controls and profits from a company reveals who can influence decisions, exposes potential conflicts of interest or hidden concentration of power, and affects transparency and risk in the stock.
indirect ownership financial
"directly held by 5AM Ventures II, L.P. ... indirect beneficial ownership reported"
pecuniary interest financial
"disclaims beneficial ownership of such securities except to the extent of its or his respective pecuniary interest"
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What did the 5AM-affiliated holders do in this Form 4 for SKYE?
They sold 33,892 shares of Skye Bioscience Common Stock on September 16, 2026 in open-market or private transactions, through 5AM Ventures II, L.P. and 5AM Co-Investors II, L.P., and reported updated indirect holdings after these sales.
What SKYE stake does 5AM Ventures VII, L.P. report in this filing?
5AM Ventures VII, L.P. reports an indirect holding of 981,269 shares of Skye Bioscience Common Stock. These securities are directly held by 5AM Ventures VII, L.P., with 5AM Partners VII, LLC as its sole general partner.
AI-generated analysis. How Rhea-AI works. Not financial advice.
